Akebia Therapeutics (AKBA) Free Cash Flow Growth (3y) (2016 - 2026)
Akebia Therapeutics (AKBA) Free Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 9.86% |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -18.92% |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 2.82% |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 45.60% |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 39.19% |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -82.02% |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 18.94% |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 114.21% |
| 10 | Akebia Therapeutics | 235.00 Mn | 72.40 Mn | 41.25 Mn | -6.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.64% |
| Dec 31, 2025 | 36.94% |
| Sep 30, 2025 | -6.06% |
| Jun 30, 2025 | 39.67% |
| Mar 31, 2025 | 14.46% |
| Dec 31, 2024 | 58.57% |
| Sep 30, 2024 | 50.81% |
| Jun 30, 2024 | 45.73% |
| Mar 31, 2024 | 35.01% |
| Dec 31, 2023 | 57.98% |
| Sep 30, 2023 | 35.88% |
| Jun 30, 2023 | -53.96% |
| Mar 31, 2023 | 41.94% |
| Dec 31, 2022 | 16.03% |
| Sep 30, 2022 | 58.69% |
| Jun 30, 2022 | 8.74% |
| Mar 31, 2022 | 46.24% |
| Dec 31, 2021 | 5.54% |
| Sep 30, 2021 | -63.95% |
| Jun 30, 2021 | -109.21% |